Investigational Therapies and Life-Cycle Management

Looking to the future – our innovative investigational therapies

Conducted from Tillotts Pharma’s headquarters, our R&D activities primarily focus on the life-cycle management of our own products and the development of innovative new treatment concepts in the digestive field. We lead large Phase III studies on a global scale, demonstrating our commitment to the commercialisation of new products and providing more treatment options for those with GI-diseases.

In addition to our current product portfolio, Tillotts has the following ongoing programmes:

Product	Indication	Active ingredient	Development phase	Partner/innovator
TP01 / Colpermin™	Irritable bowel syndrome	Peppermint oil	Launched/registration	N/A
TP02 / Asacol™ 800 mg	Mild to moderate ulcerative colitis	Mesalazine (5-ASA)	Launched/registration	N/A
TP08	Ulcerative proctitis	Mesalazine (5-ASA)	Formulation development	N/A
TP09	Familial adenomatous polyposis	Eflornithine/Sulindac	Phase III	Cancer Prevention Pharmaceuticals
TP10	Not disclosed	Not disclosed	Pre-clinical	Not disclosed
TP20b	Crohn's Disease – Life Cycle Management	Budesonide	Formulation development	N/A

PROGRAMME DESCRIPTIONS

Last update: July 2017.

All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts^®, Asacol™, Octasa^®, Fivasa™, Lixacol™, Asacolon™, Colpermin™, VistaPrep^®, Entocort^®, Entocir™, Entocord™ and Budecol™ and are either registered or applied for in up to 70 countries (transfer of registrations to Tillotts pending in certain countries). The rights to Asacol, including the rights to the trademark, are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg. The rights to Colpermin, including the rights to the trademark, are owned by Tillotts in various countries except for the following: United Kingdom and Ireland.

Product information on this website is limited, with the aim of providing a summary for general information purposes for a wide audience regarding the activities of Tillotts, and could contain product details or information not accessible or valid in your country. Tillotts disclaims responsibility for access of information which may not comply with any regulation or standard in any particular country. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.

PROGRAMME DESCRIPTIONS

TP01/Colpermin™
TP01 is a herbal medicinal product consisting of enteric coated peppermint oil capsules indicated for the symptomatic
treatment of painful bowel cramps and bloating, especially in people with irritable bowel syndrome.

TP02/Asacol™ 800 mg
TP02 aims to expand Asacol 800 mg to additional territories. New drug applications (NDAs) for TP02 for additional
territories will be filed.

TP08/Asacol™ 1000 mg
TP08 is a line extension to Asacol 500 mg suppositories.

TP09/eflornithine/sulindac
TP09 offers the potential of non-surgical pharmaco-preventive therapy across for patients with familial adenomatous
polyposis (FAP). Eflornithine/sulindac is developed by Cancer Prevention Pharmaceuticals, Inc. (CPP) and Tillotts
Pharma under a co-development framework agreement. Read the full press release here.

The current Phase III study is investigating whether the new drug combination eflornithine/sulindac is superior to sulindac
or eflornithine as single agents in delaying the time to the first occurrence of any FAP-related event. The study will also
determine if this new treatment for FAP can reduce the number and/or size of colon polyps.

Read more about the clinical trial here.

TP10
New projects in pre-clinical development are not disclosed.

Last update: May 2016.

All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts®, Asacol™, Octasa®, Fivasa™, Lixacol™, Asacolon™, Colpermin™, VistaPrep®, Entocort®, Entocir™, Entocord™, Budecol™ and Zentacort™ and are either registered or applied for in up to 70 countries (transfer of registrations to Tillotts pending in certain countries). The rights to Asacol, includingthe rights to the trademark, are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg. The rights to Colpermin, including the rights to the trademark, are owned by Tillotts in various countries except for the following: United Kingdom and Ireland.